Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6108567 | 0.88 | MCHR1 (0.82) | MCHR1 | |
| SCHEMBL6108985 | 0.86 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL6110848 | 0.86 | MCHR1 (0.76) | MCHR1MCHR2 | |
| SCHEMBL6109577 | 0.85 | MCHR1 (0.78) | MCHR1 | |
| SCHEMBL6109301 | 0.84 | MCHR1 (0.68) | MCHR1EPHX2MCHR2 | |
| SCHEMBL6109144 | 0.84 | MCHR1 (0.68) | MCHR1EPHX2MCHR2 | |
| SCHEMBL6111458 | 0.84 | MCHR1 (0.94) | MCHR1 | |
| SCHEMBL6108859 | 0.84 | MCHR1 (0.78) | MCHR1 | |
| SCHEMBL6109631 | 0.82 | MCHR1 (0.73) | MCHR1 | |
| SCHEMBL6110588 | 0.82 | MCHR1 (0.77) | MCHR1MAPTEPHX2MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | 7TM PHARMA A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| EP-1497260-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM Pharma A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004048319-A1 | NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003087045-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | GPR119, MCHR2, HCRTR2 | MCHR1 5/4885MEN1 3602/4885CYP3A4 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.